Evolving therapeutic strategies for retarding progression of diabetic nephropathy - An update for 2002

Acta Diabetologica

Volumn 39, Issue SUPPL. 2, 2002, Pages

  Epstein, M ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Calcium antagonists; Diabetes; Endstage renal disease; Hypertension; Nephropathy; Renin angiotensin system blockade

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRBESARTAN; LOSARTAN; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ENALAPRIL; LISINOPRIL; NISOLDIPINE; PLACEBO; RAMIPRIL;

ADD ON THERAPY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; HUMAN; KIDNEY FAILURE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANTIHYPERTENSIVE ACTIVITY; COMORBIDITY; DRUG ACTIVITY; DRUG EFFECT; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT PLANNING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC;

EID: 0036938640     PISSN: 09405429     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005920200025     Document Type: Conference Paper

References (21)

1. U.S. Renal Data System (2001) Annual data report: atlas of end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda
2. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP (2001) The continuing epidemics of obesity and diabetes in the United States. JAMA 286:1195-1200
3. Vora JP, Ibrahim HA, Bakris GL (2000) Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management. J Hum Hypertens 14:667-685
4. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713
5. Neuringer JR, Brenner BM (1993) Hemodynamic theory of progressive renal disease: a 10-year update in brief review. Am J Kidney Dis 22:98-104
6. Epstein M, Tobe S (2001) What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure? Current Hypertens Rep 3:422-428
7. Cooper M, Epstein M (2001) Evolving role of angiotensin II receptor antagonists in diabetes mellitus. In: Epstein M, Brunner H (eds) Angiotensin II receptor antagonists. Hanley & Belfus, Philadelphia, pp 317-330
8. Meyer TW, Anderson S, Rennke HG, Brenner BM (1987) Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int 31:752-759
9. Anderson S, Rennke HG, Brenner BM (1986) Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993-2000
10. Epstein M (1998) Calcium antagonists and renal disease. Kidney Int 54:1771-1784
11. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462
12. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, for the RENAAL Study Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869
13. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, for the Collaborative Study Group (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860
14. Estacio RO, Jeffers BW, Gifford N, Schrier RW (2000) Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23[Suppl 2]:B54-B64
15. Tarnow L, Rossing P, Jensen C, Hansen BV, Parving HH (2000) Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 23:1725-1730
16. American Diabetes Association (2001) Diabetic nephropathy (Position Statement). Diabetes Care 24:S69-S72
17. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J (2000) Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36:646-661
18. The Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145-153
19. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R (1999) Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 340:677-684
20. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755-1762
21. Epstein M, Loutzenhiser R (1990) Calcium antagonists and the kidney. Hanley & Belfus, Philadelphia, p 289